Eisbach Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$4.75M
- Investors
-
8
Eisbach General Information
Description
Developer of novel medicines designed to target chromatin regulatory mechanisms. The company focuses on molecular vulnerabilities arising in cancer genomes by leveraging epigenetic mechanisms to stop tumor growth and support new cancer therapies, enabling healthcare professionals to address unmet clinical needs.
Contact Information
Website
www.eisbach.bioCorporate Office
- Am Klopferspitz 19
- 82152 Planegg
- Germany
Corporate Office
- Am Klopferspitz 19
- 82152 Planegg
- Germany
Eisbach Timeline
Eisbach Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Grant | 26-Nov-2024 | $4.75M | Completed | Clinical Trials - Phase 1 | ||
| 7. Later Stage VC | 21-Mar-2024 | Completed | Clinical Trials - Phase 1 | |||
| 6. Grant | 29-Oct-2021 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 04-Jan-2021 | Completed | Clinical Trials - Phase 1 | |||
| 4. Seed Round | 28-Oct-2020 | Completed | Clinical Trials - Phase 1 | |||
| 3. Grant | 27-Jun-2019 | Completed | Startup | |||
| 2. Accelerator/Incubator | 01-Jan-2019 | Completed | Startup | |||
| 1. Accelerator/Incubator | 01-Jan-2019 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Eisbach Patents
Eisbach Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025242703-A1 | Crystalline forms of an alc1 inhibitor useful in the treatment of cancer | Pending | 21-May-2024 | ||
| EP-4801503-A1 | Alc1 inhibitors alc1i-1 and alc1i-2 for use in treating pancreatic cancer by potentiating the effect of irinotecan | Pending | 31-Oct-2023 | ||
| WO-2025093706-A1 | Alc1 inhibitors alc1i-1 and alc1i-2 for use in treating pancreatic cancer by potentiating the effect of irinotecan | Inactive | 31-Oct-2023 | ||
| AU-2024367467-A1 | A pyrido-thieno-pyrimidin derivative as alc1 inhibitor for use in the treatment of homologous recombination deficiency (hrd) cancers | Pending | 25-Oct-2023 | ||
| EP-4798196-A1 | A pyrido-thieno-pyrimidin derivative as alc1 inhibitor for use in the treatment of homologous recombination deficiency (hrd) cancers | Pending | 25-Oct-2023 | A61K31/519 |
Eisbach Signals
Eisbach Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cancer Prevention and Research Institute of Texas | Government | |||
| Cancer Focus Fund | Venture Capital | Minority | ||
| Bavarian Ministry of Economic Affairs and Media, Energy and Technology | Government | |||
| Bundesministerium für Bildung und Forschung | Government | |||
| Angel (individual) | Minority |
Eisbach FAQs
-
When was Eisbach founded?
Eisbach was founded in 2019.
-
Where is Eisbach headquartered?
Eisbach is headquartered in Planegg, Germany.
-
What is the size of Eisbach?
Eisbach has 14 total employees.
-
What industry is Eisbach in?
Eisbach’s primary industry is Drug Discovery.
-
Is Eisbach a private or public company?
Eisbach is a Private company.
-
What is Eisbach’s current revenue?
The current revenue for Eisbach is .
-
How much funding has Eisbach raised over time?
Eisbach has raised $12.5M.
-
Who are Eisbach’s investors?
Cancer Prevention and Research Institute of Texas, Cancer Focus Fund, Bavarian Ministry of Economic Affairs and Media, Energy and Technology, Bundesministerium für Bildung und Forschung, and are 5 of 8 investors who have invested in Eisbach.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process